Not to be confused with isopropylphenidine or N-Isopropyl-N'-phenyl-1,4-phenylenediamine, which is also called IPPD.

Isopropylphenidate (also known as IPH and IPPD) is a piperidine based stimulant drug, closely related to methylphenidate, but with the methyl ester replaced by an isopropyl ester. It has similar effects to methylphenidate but with a longer duration of action,[1][2] and was banned in the UK as a Temporary Class Drug from April 2015 following its unapproved sale as a designer drug.[3]

It has been researched as potential methylphenidate replacement for ADHD and narcolepsy, because of fewer side effects.[4][2]

See also

References

  1. ^ Markowitz JS, Zhu HJ, Patrick KS (December 2013). "Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability" (PDF). Journal of Child and Adolescent Psychopharmacology. 23 (10): 648–54. doi:10.1089/cap.2013.0074. hdl:2027.42/140321. PMID 24261661.
  2. ^ a b US application 20120245201, Markowitz JS, Patrick KS, Zhu H, "Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions", published 2012-09-27 
  3. ^ "Methylphenidate-based NPS: A review of the evidence of use and harm" (PDF). Advisory Council on the Misuse of Drugs. 31 March 2015.
  4. ^ Florence Levy (July 2014). "Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder". Pharmgenomics Pers Med: 349–356.